Research Article
Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
Table 2
Clinical characteristics of patients in the SGLT2i and control groups after propensity score matching.
| | SGLT2i () | Control () | value |
| Age (years) | 51.3 ± 9.7 | 49.4 ± 11.2 | 0.772 | Sex (male : female) | 16 : 5 | 12 : 9 | 0.190 | Follow-up period (months) | 20.1 ± 7.8 | 23.8 ± 13.6 | 0.512 | Medical history | Duration of diabetes (years) | 11.3 ± 8.9 | 11.0 ± 10.4 | 0.565 | Presence of hypertension | 10/21 | 8/21 | 0.533 | Presence of CVD | 2/21 | 3/21 | 0.634 | Initial laboratory data | HbA1c (%) | 9.6 ± 2.2 | 9.4 ± 1.9 | 0.930 | Total cholesterol (mg/dL) | 170.8 ± 45.5 | 167.2 ± 45.4 | 0.798 | Triglycerides (mg/dL) | 181.4 ± 129.7 | 136.1 ± 72.6 | 0.177 | HDL cholesterol (mg/dL) | 48.5 ± 11.6 | 44.6 ± 7.2 | 0.391 | LDL cholesterol (mg/dL) | 91.2 ± 35.3 | 100.4 ± 41.4 | 0.425 | Last laboratory data | HbA1c (%) | 8.1 ± 1.3 | 7.9 ± 1.9 | 0.804 | Total cholesterol (mg/dL) | 156.3 ± 35.6 | 150.1 ± 34.8 | 0.622 | Triglycerides (mg/dL) | 162.0 ± 90.3 | 123.1 ± 46.9 | 0.153 | HDL cholesterol (mg/dL) | 48.9 ± 9.6 | 43.9 ± 7.7 | 0.131 | LDL cholesterol (mg/dL) | 75.3 ± 25.5 | 82.1 ± 26.8 | 0.516 | Initial ETDRS score | | | 0.872 | 20, 35 (mild NPDR) | 3 | 5 | | 43, 47 (moderate NPDR) | 13 | 13 | | 53 (severe NPDR) | 2 | 2 | | 61, 65, 71, 75, 81 (PDR) | 3 | 1 | | DR severity (worsened : stable) | 3 : 18 | 11 : 10 | 0.009 | No. of IVT | 0.7 ± 1.2 | 1.5 ± 2.2 | 0.255 |
|
|
Data are presented as means ± standard deviations. CVD = cardiovascular disease; DR = diabetic retinopathy; ETDRS = Early Treatment Diabetic Retinopathy Study; HDL = high-density lipoprotein; IVT = intravitreal anti-VEGF injection; LDL = low-density lipoprotein; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; SGLT2i = sodium-glucose cotransporter 2 inhibitor. . |